Security
Organon & Co. · OGN
OGNNYSECommon stockCurrentCIK 1821825Updated Nov 2, 2026
OGN price & chart
Loading TradingView…
NYSE:OGN on TradingView ↗About the company
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.
In the news
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Organon & Co. (NYSE: OGN) ↗
Shareholder Alert: Ademi LLP investigates whether Organon & Co. is obtaining a Fair Price for Public Shareholders ↗
NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation News provided by Shareholders Foundation, Inc. Aug 13, 2025, 10:15 ET Share this article Share to X Share this article Share to X SAN DIEGO , Aug. 13, 2025 /PRNewswire/ ↗
Seeking Alpha
Organon declares $0.02 dividend ↗
Orogen Royalties Inc. (OGN:CA) Discusses New Exploration Projects and Opportunities in Global Portfolio Transcript ↗
Organon: A Merger-Arbitrage Hold With Limited Upside ↗
SEC disclosures
Organon & Co. files 8-K: Material Event ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
4 filing
SCHEDULE 13G/A - filed by VANGUARD PORTFOLIO MANAGEMENT LLC regarding Organon & Co.
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 13,552,000,000Source | 12,752,000,000Source | 13,178,000,000Source | 13,500,000,000Source | 12,154,000,000Source | 12,996,000,000Source | 13,156,000,000Source | 11,891,000,000Source | 12,867,000,000Source | 13,101,000,000Source | 12,058,000,000Source | 10,955,000,000Source |
| Property, Plant and Equipment, NetUSD | 1,290,000,000Source | 1,204,000,000Source | 1,281,000,000Source | 1,266,000,000Source | 1,162,000,000Source | 1,279,000,000Source | 1,197,000,000Source | 1,180,000,000Source | 1,303,000,000Source | 1,168,000,000Source | 1,183,000,000Source | 1,018,000,000Source |
| GoodwillUSD | 4,680,000,000Source | 4,603,000,000Source | 4,153,000,000Source | 4,680,000,000Source | 4,603,000,000Source | 4,153,000,000Source | 4,680,000,000Source | 4,603,000,000Source | 4,153,000,000Source | 4,680,000,000Source | 4,603,000,000Source | 4,603,000,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 1,130,000,000Source | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 672,000,000Source | 763,000,000Source | 1,132,000,000Source | 599,000,000Source | 704,000,000Source | 1,116,000,000Source | 547,000,000Source | 575,000,000Source | 574,000,000Source | 675,000,000Source | 693,000,000Source | 706,000,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,484,000,000Source | 1,685,000,000Source | 1,492,000,000Source | 1,484,000,000Source | 1,617,000,000Source | 1,384,000,000Source | 1,457,000,000Source | 1,547,000,000Source | 1,331,000,000Source | 1,358,000,000Source | 1,744,000,000Source | 1,475,000,000Source |
| Inventory, NetUSD | 1,488,000,000Source | 1,383,000,000Source | 1,351,000,000Source | 1,454,000,000Source | 1,287,000,000Source | 1,373,000,000Source | 1,362,000,000Source | 1,263,000,000Source | 1,406,000,000Source | 1,321,000,000Source | 1,315,000,000Source | 1,003,000,000Source |
| Assets, CurrentUSD | 4,700,000,000Source | 4,756,000,000Source | 5,111,000,000Source | 4,618,000,000Source | 4,509,000,000Source | 4,932,000,000Source | 4,371,000,000Source | 4,196,000,000Source | 4,352,000,000Source | 4,348,000,000Source | 4,508,000,000Source | 3,931,000,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | 155,000,000Source | 157,000,000Source | 173,000,000Source | 215,000,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 12,646,000,000Source | 12,259,000,000Source | 12,172,000,000Source | 12,767,000,000Source | 12,010,000,000Source | 12,093,000,000Source | 12,614,000,000Source | 11,843,000,000Source | 12,115,000,000Source | 12,629,000,000Source | 12,128,000,000Source | — |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,000,000Source | 3,000,000Source | 3,000,000Source | 3,000,000Source | 3,000,000Source | 3,000,000Source | 3,000,000Source | 3,000,000Source | 3,000,000Source | 3,000,000Source | 3,000,000Source | 3,000,000Source |
| Retained Earnings (Accumulated Deficit)USD | 1,318,000,000Source | 975,000,000Source | 1,352,000,000Source | 1,163,000,000Source | 690,000,000Source | 1,253,000,000Source | 1,026,000,000Source | 573,000,000Source | 1,109,000,000Source | 1,010,000,000Source | 443,000,000Source | -331,000,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -574,000,000Source | -571,000,000Source | -548,000,000Source | -572,000,000Source | -612,000,000Source | -539,000,000Source | -617,000,000Source | -577,000,000Source | -527,000,000Source | -649,000,000Source | -541,000,000Source | -564,000,000Source |
| Stockholders' Equity Attributable to ParentUSD | 906,000,000Source | 493,000,000Source | 1,006,000,000Source | 733,000,000Source | 144,000,000Source | 903,000,000Source | 542,000,000Source | 48,000,000Source | 752,000,000Source | 472,000,000Source | -70,000,000Source | -892,000,000Source |
| Additional Paid in Capital, Common StockUSD | 159,000,000Source | 86,000,000Source | 199,000,000Source | 139,000,000Source | 63,000,000Source | 186,000,000Source | 130,000,000Source | 49,000,000Source | 167,000,000Source | 108,000,000Source | 25,000,000Source | — |
| Liabilities and EquityUSD | 13,552,000,000Source | 12,752,000,000Source | 13,178,000,000Source | 13,500,000,000Source | 12,154,000,000Source | 12,996,000,000Source | 13,156,000,000Source | 11,891,000,000Source | 12,867,000,000Source | 13,101,000,000Source | 12,058,000,000Source | 10,955,000,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,679,000,000Source | 2,790,000,000Source | 2,616,000,000Source | 2,796,000,000Source | 2,755,000,000Source | 2,500,000,000Source | 2,615,000,000Source | 2,545,000,000Source | 2,390,000,000Source | 2,718,000,000Source | 2,918,000,000Source | 2,512,000,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | 40,000,000Source | 44,000,000Source | 46,000,000Source | 49,000,000Source |
| Accounts Payable, CurrentUSD | 1,074,000,000Source | 1,092,000,000Source | 1,051,000,000Source | 1,067,000,000Source | 1,243,000,000Source | 983,000,000Source | 1,006,000,000Source | 955,000,000Source | 952,000,000Source | 1,153,000,000Source | 1,314,000,000Source | 1,132,000,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | 116,000,000Source | 112,000,000Source | 125,000,000Source | 150,000,000Source |
| Deferred Income Tax Liabilities, NetUSD | 62,000,000Source | 56,000,000Source | 51,000,000Source | 69,000,000Source | 60,000,000Source | 56,000,000Source | 69,000,000Source | 44,000,000Source | 57,000,000Source | 74,000,000Source | 47,000,000Source | 19,000,000Source |
| Other Liabilities, NoncurrentUSD | 1,122,000,000Source | 674,000,000Source | 1,026,000,000Source | 1,121,000,000Source | 548,000,000Source | 984,000,000Source | 994,000,000Source | 549,000,000Source | 1,008,000,000Source | 977,000,000Source | 412,000,000Source | 411,000,000Source |
| Additional Financial Items | ||||||||||||
| Long-term Debt, Excluding Current Maturities | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Long-term Debt, Current MaturitiesUSD | — | 10,000,000Source | — | — | 9,000,000Source | — | 20,000,000Source | 9,000,000Source | — | 20,000,000Source | 9,000,000Source | 8,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 8,783,000,000Source | 8,739,000,000Source | 8,479,000,000Source | 8,781,000,000Source | 8,647,000,000Source | 8,553,000,000Source | 8,936,000,000Source | 8,705,000,000Source | 8,628,000,000Source | 8,860,000,000Source | 8,751,000,000Source | 8,905,000,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 19,000,000Source | 24,000,000Source | 77,000,000Source | 105,000,000Source | 101,000,000Source | 75,000,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 65,000,000Source | 85,000,000Source | -79,000,000Source | -383,000,000Source | 212,000,000Source | 123,000,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 9,000,000Source | -3,000,000Source | 13,000,000Source | 131,000,000Source | 230,000,000Source | 220,000,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 3,000,000Source | -17,000,000Source | 63,000,000Source | -160,000,000Source | -485,000,000Source | -18,000,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 225,000,000Source | 75,000,000Source | 700,000,000Source | 939,000,000Source | — | — |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 386,000,000Source | -172,000,000Source | -390,000,000Source | -513,000,000Source | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 37,000,000Source | 32,000,000Source | 162,000,000Source | 175,000,000Source | 251,000,000Source | 196,000,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 1,000,000Source | 1,000,000Source | 15,000,000Source | 22,000,000Source | 17,000,000Source | 11,000,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -38,000,000Source | -75,000,000Source | -561,000,000Source | -368,000,000Source | — | — |
| Dividends paid | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 32,000,000Source | 93,000,000Source | 1,513,000,000Source | 1,197,000,000Source | 338,000,000Source | 108,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 542,000,000Source | -128,000,000Source | -101,000,000Source | -18,000,000Source | -13,000,000Source | -31,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 672,000,000Source | 763,000,000Source | 1,132,000,000Source | 599,000,000Source | 1,116,000,000Source | 547,000,000Source | 574,000,000Source | 675,000,000Source | 693,000,000Source | 706,000,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 287,000,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -31,000,000Source | 44,000,000Source | 150,000,000Source | -76,000,000Source | 17,000,000Source | -36,000,000Source |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | — | — | — | — | 47,000,000Source | 50,000,000Source | 205,000,000Source | 145,000,000Source | 116,000,000Source | 116,000,000Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 24,000,000Source | 25,000,000Source | 25,000,000Source | 22,000,000Source | 19,000,000Source | 24,000,000Source | 77,000,000Source | 105,000,000Source | 101,000,000Source | 75,000,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 205,000,000Source | 145,000,000Source | 116,000,000Source | 116,000,000Source |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to SettlementUSD | — | — | — | — | — | — | — | — | 0Source | -1,000,000Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | 39,000,000Source | 34,000,000Source | 156,000,000Source | 132,000,000Source | 120,000,000Source | 96,000,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -17,000,000Source | -6,000,000Source | -2,000,000Source | 1,000,000Source | -7,000,000Source | 4,000,000Source | -14,000,000Source | -26,000,000Source | -42,000,000Source | -11,000,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | -3,000,000Source | 15,000,000Source | 21,000,000Source | 2,000,000Source | -40,000,000Source | 18,000,000Source |
| GoodwillUSD | — | — | 4,680,000,000Source | 4,603,000,000Source | 4,153,000,000Source | 4,680,000,000Source | 4,153,000,000Source | 4,680,000,000Source | 4,153,000,000Source | 4,680,000,000Source | 4,603,000,000Source | 4,603,000,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 301,000,000Source | — | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 9,000,000Source | 0Source | — | 9,000,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | 1,023,000,000Source | 917,000,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 83,000,000Source | -152,000,000Source | 75,000,000Source | 84,000,000Source | 67,000,000Source | 14,000,000Source | 238,000,000Source | -57,000,000Source | -350,000,000Source | 205,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 160,000,000Source | 359,000,000Source | 108,000,000Source | 145,000,000Source | 146,000,000Source | 87,000,000Source | 187,000,000Source | 864,000,000Source | 1,023,000,000Source | 917,000,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | 0Source | 90,000,000Source | 1,055,000,000Source | 1,186,000,000Source | 80,000,000Source | 0Source |
| Gain (Loss) on Disposition of Business | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,602,000,000Source | 1,582,000,000Source | 1,558,000,000Source | 1,594,000,000Source | 1,460,000,000Source | 1,513,000,000Source | 6,216,000,000Source | 6,403,000,000Source | 6,263,000,000Source | 6,174,000,000Source |
| Cost of RevenueUSD | — | — | 745,000,000Source | 659,000,000Source | 711,000,000Source | 720,000,000Source | 677,000,000Source | 672,000,000Source | 2,903,000,000Source | 2,688,000,000Source | 2,515,000,000Source | 2,294,000,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 415,000,000Source | 422,000,000Source | 434,000,000Source | 453,000,000Source | 424,000,000Source | 420,000,000Source | 1,721,000,000Source | 1,760,000,000Source | 1,893,000,000Source | 1,704,000,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 243,000,000Source | 207,000,000Source | 183,000,000Source | 229,000,000Source | 213,000,000Source | 101,000,000Source | 425,000,000Source | 807,000,000Source | 673,000,000Source | 1,122,000,000Source |
| Income Tax Expense (Benefit)USD | — | — | 83,000,000Source | -152,000,000Source | 75,000,000Source | 84,000,000Source | 67,000,000Source | 14,000,000Source | 238,000,000Source | -57,000,000Source | -350,000,000Source | 205,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 160,000,000Source | 359,000,000Source | 108,000,000Source | 145,000,000Source | 146,000,000Source | 87,000,000Source | 187,000,000Source | 864,000,000Source | 1,023,000,000Source | 917,000,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.61Source | 1.39Source | 0.41Source | 0.56Source | 0.56Source | 0.34Source | 0.72Source | 3.36Source | 4.01Source | 3.61Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.61Source | 1.38Source | 0.4Source | 0.56Source | 0.55Source | 0.33Source | 0.72Source | 3.33Source | 3.99Source | 3.59Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 259,975,000Source | 257,498,000Source | 262,611,000Source | 259,939,000Source | 260,370,000Source | 257,862,000Source | 259,495,000Source | 257,046,000Source | 255,239,000Source | 254,082,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 260,653,000Source | 259,757,000Source | 270,449,000Source | 260,156,000Source | 262,896,000Source | 261,001,000Source | 260,764,000Source | 259,152,000Source | 256,270,000Source | 255,169,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 205,000,000Source | 145,000,000Source | 116,000,000Source | 116,000,000Source |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | 0.02Source | 0.28Source | 0.02Source | 0.02Source | 0.02Source | 0.28Source | 0.34Source | 1.12Source | 1.12Source | 1.12Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 175,000,000Source | 103,000,000Source | 135,000,000Source | 223,000,000Source |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to SettlementUSD | — | — | — | — | — | — | — | — | 0Source | -1,000,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -17,000,000Source | -6,000,000Source | -2,000,000Source | 1,000,000Source | -7,000,000Source | 4,000,000Source | -14,000,000Source | -26,000,000Source | -42,000,000Source | -11,000,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 301,000,000Source | — | — | — |
| Gross ProfitUSD | — | — | 857,000,000Source | 923,000,000Source | 847,000,000Source | 874,000,000Source | 783,000,000Source | 841,000,000Source | 3,313,000,000Source | 3,715,000,000Source | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | 1,023,000,000Source | 917,000,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -793,000,000Source | -479,000,000Source | -554,000,000Source | -451,000,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | — | — | — | — | — | — | — | 4.01Source | 3.61Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | — | — | — | — | — | — | — | 3.99Source | 3.59Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Interest ExpenseUSD | — | — | 128,000,000Source | 126,000,000Source | 108,000,000Source | 131,000,000Source | 111,000,000Source | 124,000,000Source | 504,000,000Source | 520,000,000Source | 527,000,000Source | 422,000,000Source |
Filing attachments
tm2628576d1_ex99-1.htm · 8-K · 2026-10-30
Exhibit 99.1 Supplemental Financial Information This exhibit provides certain supplemental non-GAAP financial measures for the quarter ended September 30, 2026. As disclosed in the accompanying Current Report on Form 8-K, Organon & Co. (the “Company”) is furnishing this information in lieu of including such supplemental measures in a quarterly earnings release. As referenced below, the Company believes that these supplemental measures assist in understanding its financial performance, but that…
Read attachment ↗tm2621744d1_ex99-1.htm · 8-K · 2026-07-31
EX-99.1 2 tm2621744d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Supplemental Financial Information This exhibit provides certain supplemental non-GAAP financial measures for the quarter ended June 30, 2026. As disclosed in the accompanying Current Report on Form 8-K, Organon & Co. (the “Company”) is furnishing this information in lieu of including such supplemental measures in a quarterly earnings release. As referenced below, the Company believes that these supplemental measures assist in unde…
Read attachment ↗tm2613165d1_ex99-1.htm · 8-K · 2026-04-30
EX-99.1 2 tm2613165d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Media Felicia Investor Jennifer Contacts: Bisaro Contacts: Halchak ────────────────────────────────────────────────────────────── (646) (201) 275-2711 703-1807 Kate Renee Vossen McKnight (732) (551) …
Read attachment ↗d38652dex991.htm · 8-K · 2026-04-27
EX-99.1 3 d38652dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Sun Pharma signs Definitive Agreement to Acquire Organon Organon stockholders to receive US$ 14.00 per share in cash The deal values Organon at EV of US$ 11.75 billion Combined Business leverages complementary portfolios and global scale for sustained long-term value creation Mumbai, India, April 27, 2026 and Jersey City, New Jersey, April 26, 2026 - Sun Pharmaceutical Industries Limited (Reuters: SUN. BO, Bloomberg: SUNP IN, NSE:…
Read attachment ↗tm266144d1_ex99-1.htm · 8-K · 2026-02-12
Exhibit 99.1 Media Contacts: Felicia Bisaro Investor Contacts: Jennifer Halchak ─────────────────────────────────────────────────────────────────────────── (646) 703-1807 (201) 275-2711 Kate Vossen Renee McKnight (732) 675-8448 (551) 204-6129 Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025 Full year 2025 revenue of $6.2 billion, down 3% on both an as-reported basis and at con…
Read attachment ↗tm266144d1_ex99-2.htm · 8-K · 2026-02-12
Exhibit 99.2 Fourth Quarter and Full Year 2025 Earnings Organon Disclaimer statement Cautionary Note Regarding Non - GAAP Financial Measures This presentation contains “non - GAAP financial measures,” which are financial measures that either exclude or include amounts t hat are correspondingly not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Specifically, th e c ompany makes use…
Read attachment ↗